Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CCR5 | P51681 | 2/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425720 | 0.88 | PTGER1 (0.56) | PTGER1KMT2APARP1PARP2CNR1 | |
| SCHEMBL487486 | 0.88 | PTGER1 (0.75) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL12505359 | 0.87 | PARP1 (0.54) | PTGER1KMT2ALRRK2PARP1PARP2 | |
| SCHEMBL5110061 | 0.87 | PTGER1 (0.81) | PTGER1CYP2C9 | |
| SCHEMBL5460706 | 0.87 | PTGER1 (0.65) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL17041323 | 0.86 | KMT2A (0.65) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL4722050 | 0.85 | PTGER1 (0.64) | PTGER1KMT2ALRRK2CYP2C9CCR5 | |
| SCHEMBL29836110 | 0.85 | PTGER1 (0.64) | PTGER1KMT2ALRRK2CYP2C9CCR5 | |
| SCHEMBL321453 | 0.85 | PARP1 (0.57) | PARP1CYP2C9FOLH1 | |
| SCHEMBL1649274 | 0.84 | PTGER1 (0.62) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101056879-B | Purine derivatives as A3 and A1 adenosine receptor agonists | US GOVERNMENT (US) | 2011-10-05 | — | — | CN | disclosed |
| US-7825126-B2 | Purine derivatives as A3 and A1 adenosine receptor agonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825126-B2 | Purine derivatives as A3 and A1 adenosine receptor agonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1675832-B1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| CN-101056879-A | Purine derivatives as A3 and A1 adenosine receptor agonists | US GOVERNMENT (US) | 2007-10-17 | — | — | CN | disclosed |
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND H (MD) | 2007-10-04 | — | — | US | disclosed |
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND H (MD) | 2007-10-04 | — | — | US | disclosed |
| EP-1794162-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070060596-A1 | Heterocyclyl compounds | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| US-20070060596-A1 | Heterocyclyl compounds | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| US-20070060596-A1 | Heterocyclyl compounds | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| EP-1675832-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006031505-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2005040128-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060596-A1 | Heterocyclyl compounds | F9, F12, CYP2C9 | PTGER1 1257/4885KMT2A 1134/4885LRRK2 1295/4885 |
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | ADORA1, ADORA3, ADORA2A | PTGER1 62/4885KMT2A 3555/4885LRRK2 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.